Results 71 to 80 of about 60,209 (283)

30‐Day DAPT in Patients at High Bleeding Risk Undergoing PCI With Biodegradable‐Polymer Sirolimus‐Eluting Ultra‐Thin Stent

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background There is limited evidence on the safety and efficacy of biodegradable‐polymer sirolimus‐eluting ultra‐thin stent (BP‐SES) in patients at high bleeding risk (HBR) undergoing percutaneous coronary intervention (PCI). Aims This study aims to evaluate the clinical outcomes of HBR patients treated with BP‐SES and ≤ 30‐day dual ...
Andrea Erriquez, David M. Leistner, Valeria Paradies, Rita Pavasini, Matteo Serenelli, Gianni Casella, Simone Biscaglia, Christoph Naber, Gianluca Campo, Pieter C. Smits   +9 more
wiley   +1 more source

Sirolimus Monotherapy for Thrombocytopenia in Primary Antiphospholipid Syndrome: A Pilot Study From a Tertiary Referral Center

Frontiers in Immunology, 2022
BackgroundThrombocytopenia (TP) is considered as a warning sign of high-risk antiphospholipid syndrome (APS) and sometimes a paradoxical sign of anti-thrombosis treatment.
Wenhui Xie, Lanlan Ji, Zhuoli Zhang
doaj   +1 more source

The Impact of Underlying Plaque Characteristics Following the Third‐Generation Resorbable Magnesium Scaffold Implantation: An Intravascular OCT Assessment up to 12‐Months

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Third‐generation resorbable magnesium scaffold (RMS) was developed with stronger mechanical properties and thinner struts compared to its predecessor. This study aimed to assess the influence of the OCT‐derived underlying plaque characteristics on in‐scaffold late lumen loss (LLL) in patients treated with RMS up to 12‐months ...
Alp Aytekin, Masaru Seguchi, Erion Xhepa, Michael Haude, Adrian Wlodarczak, René J van der Schaaf, Jan Torzewski, Hector M. Garcia‐Garcia, Ron Waksman, Michael Joner   +9 more
wiley   +1 more source

Liver transplantation [PDF]

, 2014
Purpose of review: Long-term survival of liver transplant recipients is threatened by increased rates of de-novo malignancy and recurrence of hepatocellular carcinoma (HCC), both events tightly related to immunosuppression.
Burroughs, AK, De la Mata, M, Rodríguez-Perálvarez, M   +2 more
core  

Mechanism-based strategies for the management of autoimmunity and immune dysregulation in primary immunodeficiencies [PDF]

, 2016
A broad spectrum of autoimmunity is now well described in patients with primary immunodeficiencies (PIDs). Management of autoimmune disease in the background of PID is particularly challenging given the seemingly discordant goals of immune support and ...
Cooper, Megan A, Farmer, Jocelyn R, Foldvari, Zsofia, Torgerson, Troy R, Walter, Jolan E   +4 more
core   +2 more sources

Stent Fracture of Biolimus‐Eluting Stent (Biofreedom) Complicated With Micro‐Coronary Artery Aneurysm

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Coronary stent fractures (SFs) are an emerging complication of coronary stents. There are numerous risk factors for SF, which include vessel angulation, use of sirolimus‐eluting stent (SES), long stents, multiple stent layers, stent overlap, inflammation, hypersensitivity, stenting in the right coronary artery, heavy calcification, ostial ...
Kosuke Muto, Takahide Arai, Hiroki Hoya, Shintaro Nakano   +3 more
wiley   +1 more source

Initial sirolimus dosage recommendations for pediatric patients with PIK3CD mutation-related immunodeficiency disease

Frontiers in Pharmacology, 2022
Sirolimus is used to treat pediatric patients with PIK3CD mutation-related immunodeficiency disease. However, the initial dosages of sirolimus remain undecided.
Xiao Chen, Jinglin Wang, Jianger Lan, Xilin Ge, Hong Xu, Yu Zhang, Zhiping Li   +6 more
doaj   +1 more source

Therapeutic Drug Monitoring, Electronic Health Records, and Pharmacokinetic Modeling to Evaluate Sirolimus Drug Exposure–Response Relationships in Renal Transplant Patients [PDF]

, 2016
Sirolimus, an immunosuppressant agent used in renal transplantation, can prevent allograft rejection. Identification of the therapeutic index (ratio of minimum toxic concentration to minimum therapeutic concentration) for immunosuppresants is necessary ...
Cohen-Wolkowiez, Michael, Gonzalez, Daniel, Greenberg, Rachel, Guptill, Jeffrey T., Hill, Kevin, Hornik, Christoph, Jiang, Wenlei, Ku, Lawrence, Melloni, Chiara, Patel, Uptal D., Wu, Huali, Zheng, Nan, Zimmerman, Kanecia O.   +12 more
core   +2 more sources

In Vitro and Clinical Evaluations of UGT1A1‐, P‐gp‐, OATP1B1‐, and BCRP‐Mediated Drug–Drug Interactions of Belumosudil, a Potent ROCK2 Inhibitor

The Journal of Clinical Pharmacology, EarlyView.
Abstract Belumosudil is an oral selective rho‐associated coiled‐coil containing protein kinase 2 inhibitor, approved as a treatment for chronic graft‐versus‐host disease. Prior clinical studies demonstrated that coadministration with strong CYP3A4 inducers or proton pump inhibitors requires dose modification of belumosudil.
Olivier Schueller, Lauren Lohmer, Felix Beck, Jeegar Patel, Jasminder Sahi   +4 more
wiley   +1 more source

Perfil dos pacientes submetidos à angioplastia trasluminal coronariana com stents farmacológicos no Instituto de Cardiologia de Santa Catarina. [PDF]

, 2007
Trabalho de Conclusão de Curso - Universidade Federal de Santa Catarina. Curso de Medicina.
Aquino, Vivian Wuerges de
core